Assessment of combined α-GAL enzyme activity and lyso-GL3 for Fabry disease screening in women with chronic kidney disease

Cassiano Augusto Braga Silva; Fellype Carvalho Barreto; Osvaldo Merege Vieira Neto; Leandro Júnior Lucca; Fernando A. Vieira; Ana Paula Gueiros; Marta V. Boger; Artur Quintiliano Silva; Felipe Leite Guedes; Karla Cristina Petruccelli Israel; Gina Elizabeth Moreno Gordon; Valeria Veloso; Gabriela Sevignani; Carolina Teles Barretto; Maria Gabriela Rosa; Roberta Correa Pascotto; Gelzie Sorrentino Ennes; Eduarda M. Souza; Márcia Gonçalves Ribeiro; Luís Gustavo Modelli de Andrade

doi:10.1016/j.ymgme.2024.108565

Abstract

The spectrum of clinical presentation of Fabry disease (FD) in women is broad and challenging. The aim is to evaluate the effectiveness of an alternative screening method for FD in women.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Silva et al. (2024) studied this question.

synapsesocial.com/papers/68e5bf9fb6db643587556edc https://doi.org/10.1016/j.ymgme.2024.108565

View Full Paper

Ask AI

Bookmark

Abstract

The spectrum of clinical presentation of Fabry disease (FD) in women is broad and challenging. The aim is to evaluate the effectiveness of an alternative screening method for FD in women.

Assessment of combined α-GAL enzyme activity and lyso-GL3 for Fabry disease screening in women with chronic kidney disease

Abstract

Discussion

Cite This Study

Assessment of combined α-GAL enzyme activity and lyso-GL3 for Fabry disease screening in women with chronic kidney disease

Abstract

Discussion

Cite This Study

Keep reading

Keep reading